Cost-Effectiveness of Lorlatinib for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase Positive Advanced Non-Small Cell Lung Cancer in Spain.

Presa, María; Vicente, David; Calles, Antonio; Salinas-Ortega, Laura; Naik, Jaesh; García, Luis F; Soto, Javier

Presa, María; Vicente, David; Calles, Antonio; Salinas-Ortega, Laura; Naik, Jaesh; García, Luis F; Soto, Javier.

Afiliación

Presa M; Health Economics, Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain.
Vicente D; Medical Oncology Department, Hospital Universitario Virgen de Macarena, Sevilla, Spain.
Calles A; Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
Salinas-Ortega L; Health Economics, Pharmacoeconomics and Outcomes Research Iberia (PORIB), Madrid, Spain.
Naik J; Health Economics, BresMed Health Solutions, Sheffield, UK.
García LF; Oncology Medical, Pfizer, Madrid, Spain.
Soto J; Health Economics & Outcomes Research, Pfizer, Madrid, Spain.

Clinicoecon Outcomes Res ; 15: 659-671, 2023.

Article en En | MEDLINE | ID: mdl-37701861

Palabras clave

ALK+; advanced non-small cell lung cancer; cost-effectiveness analysis; cost-utility analysis; lorlatinib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Health_economic_evaluation Idioma: En Revista: Clinicoecon Outcomes Res Año: 2023 Tipo del documento: Article País de afiliación: España

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google